Sign up to save your podcasts
Or
Share JAMA Oncology : Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
JAMA Oncology : Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD.
Related Content:
- Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
View all episodes
By The JAMA Network
4.9
1212 ratings
Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD.
Related Content:
- Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
More shows like JAMA Network
View all
JAMA Editors' Summary
133 Listeners
Neurology® Podcast
293 Listeners
JAMA Author Interviews
162 Listeners
Diabetes Core Update
107 Listeners
JAMA Clinical Reviews
493 Listeners
EM Clerkship
809 Listeners
Mayo Clinic Talks
278 Listeners
The Curbsiders Internal Medicine Podcast
3,327 Listeners
JAMA Dermatology Author Interviews
17 Listeners
JAMA Neurology Author Interviews
14 Listeners
JAMA Psychiatry Author Interviews
23 Listeners
JAMA Surgery Author Interviews
6 Listeners
JAMA Medical News
90 Listeners
Core IM | Internal Medicine Podcast
1,114 Listeners
JAMAevidence The Rational Clinical Examination
29 Listeners
Annals On Call Podcast
192 Listeners
Psychopharmacology and Psychiatry Updates
289 Listeners
The Clinical Problem Solvers
514 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
349 Listeners
JAMAevidence JAMA Guide to Statistics and Methods
18 Listeners
The Curious Clinicians
364 Listeners
AMA Update
96 Listeners